Researchers have uncovered that a molecule used to increase the efficiency of CRISPR-Cas9 gene editing destroys parts of the genome. The team discovered that while AZD 7648 does improve efficiency, it has the unwanted side effect of destroying other areas of the genome. They argue that alternatives… Read More
This article is sponsored by SCIEX. A new era of medicine has entered clinics with drugs against sickle cell anaemia or gene-related deafness, and many more gene therapy drugs are in different stages of development. These novel approaches go beyond treating symptoms; they aim to cure diseases. However, the diversity… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More
Several recent drug discovery partnerships have been announced that reflect the importance of new technologies and techniques to the efficient development of new therapeutics. ERS Genomics and Université de Montréal ERS Genomics and Université de Montréal (UdeM) have announced an agreement that grants the university access to ERS’ CRISPR/Cas9 patent… Read More
News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More
DDW Editor Reece Armstrong speaks to Dr Sandro Ataide, Senior Lecturer in Structural Biology at the School of Life and Environmental Sciences Sydney Drug Discovery Initiative (DDI). Earlier this year, Dr Ataide’s team developed a gene-editing tool called SeekRNA that uses a programmable ribonucleic acid (RNA) strand that can directly… Read More
A new study has revealed that reducing the activity of a particular gene using CRISPR gene editing can rejuvenate stem cells in the brain to create fresh neurons. The finding in mice could open new avenues for potential therapeutics to improve brain function and reduce regenerative… Read More
Cancer Research Horizons and AstraZeneca have signed a five-year renewal of the Functional Genomics Centre, a facility dedicated to advancing drug discovery with genome-altering technologies such as CRISPR. The Functional Genomics Centre was established in 2019 to explore the function and interaction of genes and proteins… Read More
The latest episode of the DDW Highlights podcast and vodcast is now available to listen to or watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The last few days have seen some interesting developments… Read More
News round-up for 1-5 July by DDW Senior Digital Content Editor Diana Spencer. The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant… Read More
A team of researchers have discovered the bridge recombinase mechanism, a precise and powerful tool to recombine and rearrange DNA in a programmable way. The study, published in Nature, reports their discovery of the first DNA recombinase that uses a non-coding RNA for sequence-specific selection of… Read More
Intellia Therapeutics has shared the first-ever clinical data demonstrating the potential for redosing with an investigational in vivo CRISPR-based therapy. The data from the ongoing Phase I study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting. Read More
DDW’s Megan Thomas talks to Nicola McCarthy, Head of Research at the Milner Therapeutics Institute. https://www.youtube.com/watch?v=MLnELbr7Nxc MT: Could you start by giving me your name, your job title and what you do? NM: I'm Head of Research at the Milner Therapeutics Institute, which is part of the University of Cambridge, and I… Read More
Scientists at the University of Sydney have developed a gene editing tool with greater accuracy and flexibility than CRISPR. SeekRNA uses a programmable ribonucleic acid (RNA) strand that can directly identify sites for insertion in genetic sequences, simplifying the editing process and reducing errors. Read More
Lithuanian CRISPR gene editing company Caszyme has added early-stage mRNA synthesis, analysis, and optimisation to its range of offerings. The strategic development was announced at BIO2024 in San Diego, US. Caszyme CEO Dr Monika Paulė comments: “The demand for tailored gene editing solutions continues… Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
